Artrolive

Method of action: Anti-Inflammatory, Corrective Metabolism Of Bone And Cartilaginous Tissue, Mineral, Regenerative, Stimulating Regeneration Of Cartilaginous Tissue, Vitamins

Treatment option: Gonarthrosis, Osteoarthritis, Chondromalacia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Artrolive

What is Artrolive? Definitional Overview and Classification

Property	Description
Active Ingredients	Glucosamine, Chondroitin (as sulfate salts)
Form	Oral tablets, capsules, or powder for solution
Pharmacological Class	Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA)
General Purpose	Cartilage structure and function support
Origin	Derived (natural compounds from connective tissue)

What is Artrolive and What Type of Medicine is It?

Artrolive is a pharmaceutical combination product containing two primary active ingredients, Glucosamine and Chondroitin, most often formulated as their sulfate salts. Manufactured by Aché Laboratórios Farmacêuticos S/A, it holds a recognized position within the Latin American market. It is fundamentally classified as a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA). This classification identifies medications intended for a sustained approach to managing joint discomfort by targeting the underlying joint structure, distinguishing them from immediate-acting analgesics.

Composition and Differentiation: Glucosamine and Chondroitin

The composition relies on Glucosamine and Chondroitin, which are both natural compounds integral to the structure of human cartilage. Glucosamine serves as a building block for cartilage matrix components, while Chondroitin plays a role in the tissue's resistance to compression by promoting water retention within the cartilage. This dual-ingredient formulation is designed to provide the essential biological precursors for joint maintenance. Artrolive is commonly available in powder for oral solution (sachets), providing an alternative to traditional tablets or capsules for adult patients who may require easier administration.

General Benefit: Supporting Cartilage Structure and Function

The core intent of Artrolive is to act as a chondroprotective agent, focused on sustaining the integrity and health of articular cartilage. By supplying components necessary for cartilage synthesis and enhancing the tissue's ability to retain water, the medicine aims to support the overall joint structure. This mechanism is intended to assist in the long-term maintenance of joint function and movement. A typical application involves long-term supportive care for individuals experiencing joint stiffness, aiming to contribute to the joint's stability and resilience over time.

What side effects are possible with Artrolive?

Safety Information and Serious Adverse Reactions

The most critical safety information for products marketed under variations of the name Artrolive (including Artri King and Ortiga products) relates to the risk of serious and life-threatening adverse reactions from undeclared, prescription-strength drug ingredients. Regulatory warnings have been issued against purchasing or using these products due to their unapproved status and the presence of hidden active pharmaceutical ingredients (APIs).

Documented Safety Concerns and Adverse Reactions

Laboratory analyses confirmed that various products sold as Artrolive or its variants contain powerful, undisclosed drugs such as the corticosteroid Dexamethasone, the non-steroidal anti-inflammatory drug (NSAID) Diclofenac sodium, and the muscle relaxant Methocarbamol.

Reported serious adverse reactions linked to the use of these misbranded products include:

Gastrointestinal Damage: Serious damage, including internal bleeding, ulceration, and fatal perforation of the stomach and intestines, particularly from the undeclared NSAID.
Cardiovascular Events: Increased risk of events such as heart attack and stroke, associated with undeclared NSAIDs.
Endocrine and Adrenal Dysfunction: Potential for high blood glucose levels, infections, bone damage, and adrenal suppression from the undeclared corticosteroid. Sudden cessation of the product after prolonged use may lead to a dangerous withdrawal syndrome.
Liver Toxicity: Including liver failure and death in rare but documented instances.
Nervous System Effects: Sedation, dizziness, and low blood pressure from the undeclared muscle relaxant.

Safety Monitoring Notes and Restrictions

Consumers are formally advised by regulatory authorities not to purchase or use Artrolive products or its variants. Healthcare professionals are directed to evaluate patients who have used these products for potential drug-drug and drug-disease interactions related to the hidden corticosteroids, NSAIDs, and muscle relaxants. Monitoring should address potential adrenal suppression and the need for safe, controlled discontinuation of the undeclared APIs. The manufacturing process of these unapproved products is considered unreliable, meaning the presence and concentration of active ingredients may be inconsistent and dangerous.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information indicates that Artrolive (Glucosamine/Chondroitin) has a large safety margin. Toxic effects and severe symptoms are unlikely to occur, even following ingestion of doses significantly higher than recommended, based on established toxicological studies. Certain regulatory documents state that no cases of accidental or intentional overdose are known for related medicinal products.

Documented Manifestations and Actions

Classification	Official Regulatory Statement
Documented Manifestations	Symptoms following high ingestion may align with common adverse effects, including nausea, abdominal pain, diarrhea, or constipation.
Severity	Severe toxic effects are officially deemed unlikely to occur.
Antidote	No specific antidote is known; treatment is focused on symptomatic support.

Required Emergency Response

The regulatory mandate is clear: any suspected overdose or ingestion of a large quantity necessitates seeking immediate medical attention. If overdose occurs, the product must be discontinued and medical personnel will implement symptomatic and standard supportive measures, such as action to restore the hydro electrolyte balance. Patients are instructed to consult a doctor or a hospital immediately upon suspected overexposure. The regulatory profile includes a note that no dose recommendations can be given for patients with impaired renal or liver function due to a lack of data.

Therapeutic Uses of Artrolive

What Artrolive Treats: Main Uses and Benefits

Relief for Chronic Joint Pain and Stiffness

Artrolive is commonly used across conditions presenting with chronic manifestations, primarily Osteoarthritis (OA), which typically affects major joints like the knees and hips. It may be part of symptomatic management for symptoms related to physical discomfort, such as chronic discomfort and articular pain syndromes characteristic of joint wear and tear.

Its use is considered relevant in contexts involving symptoms that interfere with daily functioning, such as those associated with mild to moderate osteoarthritis of the knee. This may assist with symptoms related to physical discomfort, such as persistent ache and morning stiffness, which are the main symptoms patients seek to manage.

Quick Fact: Relief for Joint Stiffness The medication is considered relevant when supportive symptom management is appropriate for symptoms that create noticeable functional strain, particularly joint stiffness and chronic articular discomfort.

The primary indications for use may include addressing symptoms of knee osteoarthritis, hip osteoarthritis, and degenerative joint disease.

Support for Improved Physical Function

The use of Artrolive helps improve day-to-day comfort, which may assist with challenges associated with diminished physical function and impaired joint flexibility. By easing symptoms that interfere with daily functioning, Artrolive may assist individuals, particularly older adults, with maintaining functional stability during routine activities. It is relevant when supportive symptom management is appropriate, as it contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Official regulatory documents strictly define the population groups permitted to use Glucosamine/Chondroitin products, such as Artrolive, and those who are excluded.

Age Group	Regulatory Status
Children and Adolescents (under 18)	Not Recommended/Prohibited. Safety and efficacy have not been established [3.1].
Adults (18 and older)	Permitted. Approved for use under standard labeled conditions [3.1].

Condition/Status	Regulatory Restriction
Hypersensitivity/Allergy	Contraindicated. Must not be used in patients with shellfish allergy or hypersensitivity to Glucosamine or any excipients [1.1].
Pregnancy/Breastfeeding	Not Recommended. Should not be used due to inadequate safety data [3.2].
Impaired Glucose Tolerance (Diabetics)	Caution Advised. Requires close monitoring of blood sugar levels [1.1].
Asthma	Caution Advised. Patients should be aware of potential worsening of symptoms [1.1].

Administration to patients with severe hepatic or renal insufficiency should be under medical supervision [3.3].

What should I know about interactions with other medicines?

Artrolive’s interaction profile is defined by official warnings from regulatory authorities regarding its co-administration with specific medicinal products. The most significant concern involves a documented pharmacodynamic interaction with coumarin-derived anticoagulants.

Interacting Substance	Official Interaction Pattern	Regulatory Classification
Coumarin Anticoagulants (e.g., Warfarin)	Increased anticoagulant effect and elevated International Normalized Ratio (INR). This interaction is associated with a heightened risk of bleeding.	Classified as a clinically significant interaction in official regulatory reviews, often requiring cessation or close monitoring.
Acetaminophen (Paracetamol)	Co-administration may reduce the effectiveness of both Artrolive's components and the analgesic medication.	Documented as a potential alteration of pharmacological effect.

This interaction profile also contains population-specific constraints concerning the management of blood glucose. Due to the composition of Artrolive, individuals taking antidiabetic agents should monitor blood glucose concentrations closely when starting or discontinuing use, as the component Glucosamine may influence required insulin or oral hypoglycemic doses.

No official regulatory documentation mandates a specific timing separation for Artrolive, nor does it define interactions based on CYP enzyme inhibition or induction. All documented statements focus exclusively on these clinically relevant outcome patterns described in regulatory advisories issued by health authorities globally.

Mechanism of Action

How Artrolive Works

Artrolive operates by modulating the Mevalonate Pathway, a critical metabolic route responsible for synthesizing sterol and non-sterol isoprenoids. Its core mechanism involves the structural binding and subsequent competitive inhibition of Farnesyl Pyrophosphate Synthase ( FPPS), an essential prenyltransferase enzyme. This FPPS inhibition blocks the conversion of farnesyl pyrophosphate ( FPP) into geranylgeranyl pyrophosphate ( GGPP), a key intermediate.

By limiting GGPP availability, Artrolive selectively interferes with the post-translational modification process known as protein prenylation. Specifically, it prevents the geranylgeranylation of small signaling proteins, including Rho, Rac, and Rab GTPases. These GTPases require prenylation for proper membrane localization and subsequent activation. The resulting impaired activation of these signaling proteins dampens their downstream effects, leading to a profound modulation of intracellular communication.

This cascade directly impacts the signaling pathway responsible for osteoclast function and survival. The lack of properly localized GTPases inhibits the formation of the osteoclast ruffled border, disassembling the cytoskeletal structure necessary for the cell's activity. The system-level physiological consequence is a targeted biochemical inhibition of bone remodeling activity via suppression of the osteoclast molecular machinery.

Dosage and Administration Information

How Artrolive is Used: Official Administration Guidelines

Artrolive is a symptomatic slow-acting drug for osteoarthritis (SYSADOA) and is administered exclusively through the oral route. The standard usage patterns are defined by the required long-term commitment and specific preparation for its various forms.

The medicine is used according to a structured protocol, focusing on a daily dose and sustained duration rather than acute symptom management.

Parameter	Official Administration Rule
Standard Adult Daily Dose	1500 mg of Glucosamine Sulfate equivalent.
Frequency Pattern	Typically once daily, often via the full-strength dose in a sachet, or through a divided dose regimen for capsules/tablets.
Timing & Preparation	It is commonly taken preferably at meals. Powder for oral solution must be dissolved in a glass of water before ingestion.
Duration of Course	Treatment is generally long-term. Continuous use is not intended for acute symptoms; symptom relief may require several weeks of administration.
Re-evaluation Point	If no symptom relief is experienced after 2 to 3 months of continuous use, the regimen should be re-evaluated.

Labeled Population Rules

Artrolive is not recommended for use in the pediatric population (individuals under 18 years of age), as the safety and efficacy profiles have not been established in this group. For otherwise healthy older adults, a dose adjustment is not generally required. In cases of severe renal or hepatic impairment, administration should occur under close medical supervision.

This structure defines a standardized, non-acute approach to the administration of Artrolive, focusing strictly on procedural requirements.

Recent Clinical Evidence

Research evidence / Overview of Studies for Artrolive

Evidence for Use in Mild to Moderate Knee Osteoarthritis

The research landscape for the Glucosamine and Chondroitin combination is dominated by studies related to knee osteoarthritis. Researchers have conducted numerous Randomized Controlled Trials (RCTs) and pooled data from Systematic Reviews to explore how symptoms change over time in adults and older adults experiencing mild to moderate discomfort. These studies primarily examined outcomes related to physical discomfort, including patient-reported changes in pain intensity and outcomes reflecting daily functioning or activity level.

Studies report how symptoms evolved in the observed populations. Some research describes patterns observed when certain pharmaceutical-grade formulations were used, particularly in subgroups of patients who began the study with more noticeable functional limitations. Findings, however, were mixed across the entire body of evidence, and large-scale studies often did not describe differences in patient outcomes compared to a placebo. The evidence base contributes to understanding symptom patterns, but research results apply only to the specific populations studied under research conditions.

Evidence for Use in Osteoarthritis of the Hip

The evidence base for the use of the combination product for osteoarthritis affecting the hip joint is less extensive than for the knee. The research base includes a smaller number of dedicated RCTs, and findings are often derived from analyses that include patients with hip involvement alongside knee patients. Research so far indicates that the findings for hip osteoarthritis are limited and heterogeneous. Evidence from knee studies may not be applicable to the hip joint. The research base describes how patients reported their experience but does not establish a clear, consistent pattern of change in outcomes for the hip joint compared to placebo.

Evidence Gaps and Areas of Scientific Uncertainty

The research landscape for Artrolive and its active ingredients is marked by inconsistent findings and mixed regulatory opinions. Key limitations include that the results apply only to the populations studied. Certainty remains low because many RCTs have not found differences in symptomatic outcomes between the combination product and placebo in the overall patient group. Follow-up durations were limited in some studies, and there is limited information for long-term outcomes in certain patient subgroups. Evidence comparing the product to other existing options in clinical practice is also limited.

Frequently Asked Questions (FAQ)

Common questions about Artrolive (FAQ)

Q: What exactly is Artrolive used for, besides the main conditions listed?

Official documentation for Artrolive’s active ingredients, Glucosamine and Chondroitin, describes their use primarily for the relief of symptoms in mild to moderate osteoarthritis, mainly affecting the knee joint. The labeled use described in official documents focuses on this indication. Other conditions, such as rheumatoid arthritis, are not listed in official regulatory documents as approved uses.

Q: Can Artrolive be taken by people who are vegetarian or vegan?

Glucosamine, one of the main active ingredients, is frequently derived from the shells of shellfish. While synthetic or plant-based forms exist, the official labeling for the specific Artrolive formulation should be consulted to confirm the source of its ingredients. Users following vegetarian or vegan diets may wish to consult the official product labeling to verify the ingredient source.

Q: What are the most common reasons someone might stop taking Artrolive?

Regulatory documents describe reasons why the use of Artrolive might be discontinued. Official guidelines indicate that if symptom relief is not noticed after a defined period (e.g., two to three months), the treatment regimen is generally subject to re-evaluation by a health professional. Additionally, some common, mild gastrointestinal side effects like nausea, diarrhea, or constipation are described in official documents as potential reasons for discontinuing use.

Q: Does Artrolive affect blood pressure?

General research summarized in authoritative sources suggests that the active ingredients in Artrolive do not appear to cause an increase in blood pressure for most users. However, because some medical reports have noted increased blood pressure, it is descriptive to know that monitoring blood pressure may occur when use is initiated.

Q: Is it okay to drink alcohol while using Artrolive?

Regulatory documents do not contain a specific documented interaction or warning related to the consumption of alcohol while using Artrolive. The focus of official warnings is on drug-drug interactions with specific medications, such as blood thinners and anti-diabetic agents, rather than alcohol.

Q: Is Artrolive known to cause weight gain or loss?

In clinical trials for the active ingredients, body weight changes have, in some instances, been listed as a reported adverse event. However, official information does not establish a clear, consistent pattern indicating Artrolive is definitively associated with either weight gain or weight loss in the user population.

Q: Are there any specific foods I should avoid while on Artrolive?

Official regulatory documentation for Artrolive does not specify any particular foods that must be avoided during its use. Official administration guidelines state that the product is commonly taken preferably at mealtimes.

Q: Is the full list of ingredients in Artrolive publicly available?

Regulatory requirements mandate that all approved medicinal products list their active ingredients and all excipients (inactive ingredients) in official documents like the Summary of Product Characteristics (SmPC). This complete composition information is generally made publicly available by the relevant national regulatory authority where the product has received approval.

Q: Is Artrolive meant to be a permanent treatment?

Artrolive is classified as a symptomatic slow-acting drug intended for the long-term management of chronic joint conditions. While this suggests sustained use, official guidance describes that the treatment regimen is generally subject to re-evaluation by a health professional if symptom relief is not experienced after a period of initial use.

Q: Can Artrolive affect cholesterol levels?

Evidence summarized in authoritative sources indicates that the active ingredients in Artrolive do not appear to increase cholesterol levels. Past concerns that Glucosamine might influence cholesterol levels are generally not supported by current research.

Q: Is it normal to feel a change in bowel movements when starting Artrolive?

Changes to bowel movements are included in the list of commonly reported adverse reactions described in official product information for the active ingredients. These mild gastrointestinal effects can include feeling symptoms such as diarrhea and constipation.

Q: What does official guidance say about Artrolive and driving/operating machinery?

Official guidance describes that if an individual experiences side effects such as headache, dizziness, fatigue, or visual disturbances, the ability to safely drive a car or operate machinery may be affected. Users should be aware of the potential for these effects described in the product information.

Q: Does Artrolive have a risk of dependence or addiction?

Dependence or addiction is not listed as a documented risk associated with the use of Glucosamine and Chondroitin in official drug safety reviews. These active ingredients are not classified as controlled substances by regulatory authorities.

How should Artrolive be stored and disposed of?

How to Store and Dispose of Artrolive? — Official Regulatory Status

Official storage and disposal instructions for medicines are documented in regulatory sources such as the FDA Prescribing Information or the EMA Summary of Product Characteristics (SmPC). A thorough search of these authoritative government sources did not yield a specific drug monograph for a product named Artrolive containing mandatory, officially labeled storage, stability, handling, or disposal requirements.

Consequently, no explicit government-mandated instructions are available regarding storage temperature, protection from light or moisture, in-use stability, or specific disposal procedures (such as 'do not flush'). Lacking a product-specific regulatory basis, general drug handling principles apply, but they do not replace official labeling.